The short interest to Karyopharm Therapeutics Incorporated’s float is 47.75%. The firm past twelve months price to sales ratio was 19122.01 and price to cash ratio remained 9.27. Stock’s minimum price target estimates has been figured out at $9.00 while the maximum price target forecast is established at $28.00, if we look at the price target with an optimistic approach it has upside potential of 206% from its latest closing price of $9.14. Analyst expected twelve month price target of $29.39.
Advertisement
8/18/2016 – Karyopharm Therapeutics is now covered by analysts at HC Wainwright. The one year target stock price is $16.56 with three firms rating the stock a strong buy, three firms rating the company a buy, one analyst rating the stock a hold, one analyst rating the company to underperform, and lastly 0 firms rating the company as sell.
Karyopharm Therapeutics Inc. reported its last Earnings on Aug 04 BMO where the company reported Actual EPS of $-0.84/Share whereas, the Analyst Estimated EPS was $-0.76/share. It serves the healthcare industry throughout the United States. State Street Corp raised its stake in Karyopharm Therapeutics by 5.8% in the first quarter.
8/4/2016 – Karyopharm Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. With the last stock price close up 14.37% from the 200-day moving average, compared to the S&P 500 Index which has held steady over the date range. However previously on 1/6/2016 it was downgraded by Jefferies from Buy to Hold. Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s shares are now trading -52.90% away from the 52-week high price of $19.41 and +89.23% far from the 52-week low price of $4.83. The company has market value of $322.82M.
During the last trading session, the stock’s price changed +11.19% above its 200 day moving average of $8.07 and moving +18.09% upbeat it’s SMA 50 of $7.60. A 10% Owner at Karyopharm Therapeutics, Inc. The company reported ($0.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.08.
According to Zacks brokerage recommendations, Karyopharm Therapeutics, Inc. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of USA and global copyright law. A 10% Owner in the company, Chione Ltd, on Monday June 13, 2016 collected $60,200 from the sale of 7,074 shares at a per-share price of $8.03. The number of shares now owned by investors are 37.62 mln. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company.
Advertisement
The quickest development path for a cancer drug in the USA often involves testing an experimental drug in patients who have run out of now approved treatment options. The Company’s segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
